Jenburkt Pharmaceuticals Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

4.41

4.59

4.59

4.59

4.59

Share application money

-

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

117.98

112.79

93.88

75.41

72.88

Loan funds

Secured loans

2.44

5.82

3.71

3.44

7.47

Unsecured loans

-

-

-

-

-

Total

124.83

123.20

102.18

83.44

84.93

Uses of funds

Fixed assets

Gross block

32.43

30.70

30.50

27.74

26.38

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

21.99

19.30

19.95

17.99

16.79

Net block

10.45

11.40

10.55

9.74

9.59

Capital work-in-progress

0.96

0.21

0.38

2.10

0.99

Investments

11.18

7.96

6.75

4.07

5.38

Net current assets

Current assets, loans & advances

119.23

123.38

102.70

88.16

86.87

Less : current liabilities & provisions

16.98

19.75

18.20

20.63

17.89

Total net current assets

102.25

103.63

84.50

67.53

68.98

Miscellaneous expenses not written

-

-

-

-

-

Total

124.83

123.20

102.18

83.44

84.93

Notes:

Book value of unquoted investments

-

-

0.25

1.57

3.52

Market value of quoted investments

11.18

7.96

3.93

2.50

1.86

Contingent liabilities

19.55

16.61

16.48

16.61

16.58

Number of equity sharesoutstanding (Lacs)

44.13

45.89

45.89

45.89

45.89